An Interview with Dr. Anne Hellebust, Director of Product
An Interview with Dr. Anne Hellebust, Director of Product.
An Interview with Dr. Anne Hellebust, Director of Product Read More »
HALO
RNAscope common questions, troubleshooting, and tips and tricks
When performing RNAscope image analysis, you can set yourself up for success with a combination of thoughtful experimental design, rigorous assay execution and validation. At Indica Labs, the most common challenges we see in RNAscope image analysis include chromogenic staining that has saturated to black, which causes color deconvolution challenges, loss of nuclear morphology due to over-digestion of tissue, and failing to verify and validate an image analysis solution before scaling up.
RNAscope common questions, troubleshooting, and tips and tricks Read More »
Tumor-specific tumor-resident cytotoxic T cells predict recurrence in stage III melanoma patients treated with adjuvant immunotherapy
20 January 2022 | In this 60-minute webinar, learn how HALO and HALO AI collaborate to perform tissue and cell segmentation, quantification of T-cell subsets in tumor regions, and spatial analysis .
A Deep Learning Convolutional Neural Network Can Differentiate Between Helicobacter Pylori Gastritis and Autoimmune Gastritis with Results Comparable to Gastrointestinal Pathologists
13 January 2022 | In this 60-minute webinar, researchers and pathologists from the University of New Mexico will discuss their recently published study using the HALO AI deep learning convolutional neural network (CNN) to determine whether a CNN can differentiate autoimmune gastritis from Helicobacter pylori gastritis.
2021 Masterclass: HALO AI Deep Dive on the Validation Workflow
16 December 2021 | In this Masterclass webinar we will delve into one of the latest AI tools, the AI validation workflow (available as of the HALO v3.3 release). This tool can be used to answer the question How good is my trained AI network?
2021 Masterclass: HALO AI Deep Dive on the Validation Workflow Read More »
Bench-to-Bedside Transition of Novel HALO® Assays into Clinical Trials with HALO AP®
10 December 2021 | In this 1-hour webinar, featured speakers will demonstrate end-to-end how to develop a quantitative assay in HALO and transition it into clinical trials using HALO AP.
Bench-to-Bedside Transition of Novel HALO® Assays into Clinical Trials with HALO AP® Read More »
Leveraging the collaborative image management platform, HALO Link, for multi-site image analysis collaborations
03 December 2021 | In this webinar you will learn how the Pharma Services team at Indica Labs uses HALO Link to collaborate with customers, to launch and display image analysis results, and to archive studies
2021 Masterclass: Deep Dive into AI-Based Nuclear Segmentation and Phenotyping Part II
04 November 2021 | Following up on our HALO 3.2 Masterclass: Deep Dive into AI-based Nuclear Segmentation and Phenotyping, in this Masterclass webinar with HALO 3.3, we will further delve into options for AI-based nuclear segmentation and phenotyping.
2021 Masterclass: Deep Dive into AI-Based Nuclear Segmentation and Phenotyping Part II Read More »
THYROID MALT LYMPHOMA: SELF-HARM TO GAIN POTENTIAL T-CELL HELP
28 October 2021 | The development of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) is driven by chronic inflammatory responses and acquired genetic changes. To investigate its genetic bases, we performed targeted sequencing of 93 genes in 131 MALT lymphomas including 76 from the thyroid. We found frequent deleterious mutations of TET2 (86%), CD274 (53%), TNFRSF14 (53%) and TNFAIP3 (30%) in thyroid MALT lymphoma.
THYROID MALT LYMPHOMA: SELF-HARM TO GAIN POTENTIAL T-CELL HELP Read More »
Automated detection and quantitation of gastric immune cells in a mouse model of Helicobacter pylori-driven preneoplastic progression
21 October 2021 | Gastric cancer is the fourth-leading cause of cancer death worldwide. About 80% of cases are attributable to infection with the bacterium Helicobacter pylori (Hp). Untreated Hp infection causes lifelong stomach inflammation that does not eradicate the bacterium. In some individuals, stomach inflammation leads to preneoplastic progression, a series of sequential tissue changes including loss of gastric acid-producing parietal cells, metaplasia, dysplasia, and finally cancer.